Results 11 to 20 of about 424,058 (165)
Safety and Immunogenicity of an mRNA-1273 Booster in Children [PDF]
Clinical Infectious DiseasesBackground: A 2-dose mRNA-1273 primary series in children aged 6 months-5 years (25 µg) and 6-11 years (50 µg) had an acceptable safety profile and was immunogenic in the phase 2/3 KidCOVE study.
Sharon Nachman +2 more
exaly +3 more sources
EClinicalMedicine, 2022 Summary: Background: Although effective mRNA vaccines for SARS-CoV-2 infection have been deployed worldwide, their interchangeability could facilitate the scale-up of vaccination programs.
Cécile Janssen +26 more
doaj +2 more sources
Safety outcomes associated with the moderna COVID-19 vaccine (mRNA-1273): a literature review
Expert Review of Vaccines, 2023 Introduction Current safety data from Phase 3 clinical trials have concluded that apart from transient local and systemic reactions, no safety concerns were identified for the Moderna COVID-19 vaccine (mRNA-1273).
Angel Shabu, Prasad S. Nishtala
doaj +2 more sources
Reactogenicity to the mRNA-1273 Booster According to Previous mRNA COVID-19 Vaccination [PDF]
Vaccines, 2022 The objective of this study was to assess the local and systemic adverse reactions after the administration of a COVID-19 mRNA-1273 booster between December 2021 and February 2022 by comparing the type of mRNA vaccine used as primary series (mRNA-1273 or
Oleguer Parés-Badell +12 more
doaj +2 more sources
Myocarditis and pericarditis in individuals exposed to the Ad26.COV2.S, BNT162b2 mRNA, or mRNA-1273 SARS-CoV-2 vaccines [PDF]
Frontiers in Cardiovascular Medicine, 2023 ImportanceThere is a high level of public and professional interest related to potential safety issues of the COVID-19 vaccines; however, no serious adverse cardiovascular events were reported in phase 3 randomized controlled trials of their safety and ...
Manan Pareek +6 more
doaj +2 more sources
Vaccines, 2022 Although numerous COVID-19 vaccines are effective against COVID-19 infection and variants of concern (VOC) in the real world, it is imperative to obtain evidence of the corresponding vaccine effectiveness (VE).
Shuailei Chang +8 more
doaj +2 more sources
Vaccines, 2023 Safety data following the COVID-19 booster mRNA vaccine in solid cancer patients are scarce. We prospectively evaluated adverse events after a booster dose of the BNT162b2 vaccine as compared to the mRNA-1273 vaccine in solid malignancy patients who had ...
Passakorn Wanchaijiraboon +10 more
doaj +2 more sources
Comparison of mRNA Vaccinations with BNT162b2 or mRNA-1273 in Anti-CD20-Treated Multiple Sclerosis Patients [PDF]
, 2022 Objective: Anti-CD20-treated patients are at risk of a reduced humoral immune response during the SARS-CoV-2 pandemic. Our aim was to compare the antibody response after two vaccinations with the mRNA vaccines BNT162b2 or mRNA-1273 in patients with ...
Kamber, Nicole +21 more
core +1 more source
Journal of the Formosan Medical Association, 2023 Background/Purpose: MVC-COV1901 is a protein vaccine based on the same SARS-CoV-2 strain used in mRNA vaccine mRNA-1273. Data are lacking on immunogenicity and safety of MVC-COV1901 as heterologous boost for people already received one dose of mRNA-1273.
Szu-Ting Huang +7 more
doaj +1 more source
Journal of the Formosan Medical Association, 2022 Background/Purpose: Efficacy and safety data of heterologous prime-boost vaccination against SARS-CoV-2 remains limited. Methods: We recruited adult volunteers for homologous or heterologous prime-boost vaccinations with adenoviral (ChAdOx1, AstraZeneca)
Wang-Huei Sheng +12 more
doaj +1 more source